The current standard of care for NAFLD consists of lifestyle changes, such as diet and exercise, and the treatment of common co-morbidities, such as diabetes, hypertension and dyslipidaemia (2, 4) . The management of patients with fatty liver disease already constitutes a great social and economic burden for national health services, having 26% higher costs over a 5-year follow-up (5) .
At present, the gold standard for NASH diagnosis is liver biopsy (4) -an expensive, invasive and time-consuming procedure with many risks of complications. Reliable non-invasive diagnostic tools are not available yet, so there is still an unmet medical need for a method to detect NASH at its early stages in order to prevent progression of the disease to more severe forms.
Squamous cell carcinoma antigen (SCCA) is a serine protease inhibitor that belongs to the family of serpins (6) . SCCA is physiologically found in the normal squamous epithelium, and it is over-expressed in cancers of epithelial origin (6) and in HCC liver tissue (7, 8) . In patients with HCC, serological concentration of the free form of SCCA is low, while the immune-complex SCCA-IgM is detectable at high levels (9) . Indeed, SCCA-IgM has been validated as a serological biomarker for HCC and other liver diseases, including NASH. A recent study showed that a high concentration of SCCA-IgM in the serum of HCV-positive patients is independently associated with the presence of NASH in the liver (10) .
The aim of our study was to create an algorithm that combines SCCA-IgM levels with other common clinical data to provide the probability of a patient with HCV having NASH.
Methods

Patients
The Division of Gastroenterology and Endoscopy of Verona's University Hospital, Italy, prospectively enrolled 91 patients. Inclusion criteria were: Caucasian race, HCV infection and histologically proven chronic liver disease. Exclusion criteria included: previous antiviral treatment, decompensated cirrhosis, co-infection with other viruses or concomitant medical conditions.
For each patient, the following clinical variables were collected: age, sex, weight, height, body mass index, abdomen circumference, smoke habit, presence of hypertension, obesity or metabolic syndrome, alcohol and coffee intake, liver biopsy result, presence of cirrhosis, steatosis, non-alcoholic steatosis or NASH.
Blood samples were collected before any antiviral treatment and were tested for the following markers: HCV genotype and RNA levels, platelets, white blood cells, haemoglobin (Hb), ferritin, homeostasis model assessment (HOMA) of β-cell function, insulin, glycaemia, low density lipoprotein, high density lipoprotein (HDL), aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transferase, bilirubin, cholesterol, triglycerides, and SCCA-IgM.
The study was performed in accordance with the principles of the Declaration of Helsinki and its appendices, and after approval from Verona's University Hospital Institutional Review Board and Ethics Committee. All patients gave fully informed consent authorising the use and analysis of clinical data, blood and liver tissue samples for research purposes.
Serological markers determination
Serum levels of SCCA-IgM were quantified using Hepa-IC ELISA kit (Xeptagen, Venice, Italy), following the manufacturer's instructions. Data were processed with Xerepro software (Xeptagen) and concentration of SCCA-IgM was expressed as arbitrary units per millilitre (AU/mL). All other serological markers were assessed using conventional methods.
Statistical analysis
Statistical analysis was performed using SPSS v. 16 .0.1 (IBM). For all comparisons, a P-value <0.05 was accepted as statistically significant. Data sets were analysed using the following methods: correlation analysis, principal component analysis (PCA), linear discriminant analysis (LDA), logistic regression (LR), and receiver operating characteristic (ROC) curves.
results
Patients study group
A total of 91 patients were enrolled. There were 14 subjects with negative or uncertain diagnosis of NASH that were excluded from our analysis; the remaining 77 subjects were divided in two groups: 10 patients with (NASH = 1) and 67 patients without NASH (NASH = 0).
A limited number of subjects had cirrhosis (5/77, 6.5%); most patients had steatosis <5% (46/75, 61.3%), and a small fraction had steatosis ≥33% (10/75, 13.3%). Most patients were infected with HCV genotype 1 (40/77, 51.9%).
Compared to those without NASH, patients with NASH showed significantly higher levels of insulin, ferritin, Hb, SC-CA-IgM and HOMA (P<0.05), and lower levels of HDL (P<0.05) (Tab. I).
Correlation analysis
A tau test was performed to determine if there was a correlation between NASH and one or more clinical parameters. Our analysis revealed a statistically significant correlation between histological presence of NASH and the levels of insulin, HOMA, Hb, and SCCA-IgM (P<0.01), and also between NASH and smoke, HDL and ferritin concentration (P <0.05) (Tab. II).
Principal component analysis
Based on the correlation analysis results, we analysed the data with two PCAs performed on a correlation matrix. 0.005 ALT = alanine aminotransferase; AST = aspartate aminotransferase; BMI = body mass index; GGT = γ-glutamyl transferase; Hb = haemoglobin; HCV-RNA = hepatitis C virus-RNA; HDL = high density lipoprotein; HOMA = homeostasis model assessment; LDL = low density lipoprotein; NASH = non-alcoholic steato-hepatitis; SCCA-IgM = squamous cell carcinoma antigen-IgM; WBC = white blood cells.
Development of a novel diagnostic algorithm
Linear discriminant analysis
We performed two LDAs based on the correlation analysis findings. By combining the serological parameters with a highly significant correlation with NASH (insulin, HOMA, Hb and SCCA-IgM) we obtained the formula: 
Logistic regression
We performed a binary LR using only the biomarkers with a strong correlation with NASH (insulin, HOMA, Hb and SCCA-IgM), obtaining this equation: Other two regression analyses were performed using all markers with a correlation with NASH and applying a stepwise regression. The first approach was a forward selection, which gave this final formula:
The second approach consisted of a backward elimination and produced the following equation: 
Receiver operating characteristic curves
We calculated the ROC curves of individual variables and their combinations for the identification of NASH in our patients. Compared to the use of a single marker, the combination of four, six or seven variables produced a bigger AUC (Tab. III). The highest AUC value (0.880) was obtained with the combination LR 7 , which included all seven variables correlated with NASH. Among the single markers, SCCA-IgM showed the best AUC (0.786).
conclusions
In HCV-positive patients, steatosis is common and it may promote the development of NASH (3); in addition, steatosis and NASH may induce faster liver fibrosis and evolution towards HCC (3). In order to avoid a quicker growth of liver cancer, it is important to identify patients with NASH and start treatment as early as possible. We showed that an algorithm combining SCCA-IgM serological levels with other common clinical data is a promising diagnostic tool for the detection of NASH in HCV patients, and it could improve the current methods to diagnose and monitor the disease in these patients.
Our analysis revealed seven clinical variables significantly correlated with the histological presence of NASH: insulin, HOMA, Hb, SCCA-IgM, smoke, HDL and ferritin. Our result confirms previous findings, which showed an association between NASH and insulinaemia, insulin resistance (3), Hb (11), elevated HOMA (12) and ferritin (13) , and lower HDL levels (14) in HCV patients.
SCCA-IgM has been shown to be independently associated with presence of NASH in patients with HCV infection (10) , and in our study it was the single variable with the best association with NASH. These findings support the use of SCCA-IgM to identify those patients with liver disease with a higher risk of progression to more severe stages.
The combination of multiple clinical parameters showed a higher correlation with NASH than any single marker. It is well known that the combination of multiple variables increases the accuracy of diagnostic algorithms; indeed, others have developed systems that combine various clinical values to identify patients with or at risk for NASH: the apoptosis panel (15) , the NASH diagnostic panel (16) , the oxNASH score (17) , the NASH test (18) , the Palekar test (19) and the Shimada index (20) . However, none of these models was created specifically for HCV patients.
To our knowledge, the algorithms that we present are the first ones that may be used specifically to identify NASH in patients with HCV infection. The major limit of our study is the small number of patients that were available for the analysis; further validations in larger cohorts of patients are needed to confirm our findings.
